Universal Beteiligungs und Servicegesellschaft mbH Acquires 89,122 Shares of Edwards Lifesciences Corporation $EW

Universal Beteiligungs und Servicegesellschaft mbH lifted its holdings in Edwards Lifesciences Corporation (NYSE:EW) by 6.4% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,484,222 shares of the medical research company’s stock after purchasing an additional 89,122 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH’s holdings in Edwards Lifesciences were worth $116,081,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of the business. Quantbot Technologies LP bought a new position in Edwards Lifesciences during the first quarter valued at about $26,000. SouthState Corp acquired a new position in shares of Edwards Lifesciences during the 1st quarter valued at about $27,000. Rosenberg Matthew Hamilton bought a new position in shares of Edwards Lifesciences in the 2nd quarter valued at approximately $28,000. Costello Asset Management INC acquired a new stake in Edwards Lifesciences in the 1st quarter worth approximately $29,000. Finally, NewSquare Capital LLC lifted its holdings in Edwards Lifesciences by 57.8% in the 2nd quarter. NewSquare Capital LLC now owns 366 shares of the medical research company’s stock worth $29,000 after purchasing an additional 134 shares during the last quarter. 79.46% of the stock is owned by institutional investors and hedge funds.

Edwards Lifesciences Stock Performance

NYSE:EW opened at $86.35 on Friday. The firm’s 50-day moving average is $78.20 and its 200-day moving average is $77.73. Edwards Lifesciences Corporation has a 52-week low of $65.31 and a 52-week high of $87.21. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.87 and a current ratio of 4.68. The company has a market cap of $50.11 billion, a price-to-earnings ratio of 12.42, a PEG ratio of 3.97 and a beta of 1.03.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Thursday, October 30th. The medical research company reported $0.67 earnings per share for the quarter, topping analysts’ consensus estimates of $0.59 by $0.08. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.The business had revenue of $1.55 billion for the quarter, compared to the consensus estimate of $1.49 billion. During the same period last year, the business earned $0.67 earnings per share. The firm’s revenue for the quarter was up 14.7% compared to the same quarter last year. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS. Q4 2025 guidance at 0.580-0.640 EPS. Equities research analysts anticipate that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current year.

Wall Street Analyst Weigh In

Several brokerages have commented on EW. Barclays reiterated an “overweight” rating and set a $99.00 price target (up previously from $95.00) on shares of Edwards Lifesciences in a report on Friday, October 31st. Wells Fargo & Company lifted their target price on shares of Edwards Lifesciences from $84.00 to $88.00 and gave the stock an “overweight” rating in a report on Thursday, August 7th. Sanford C. Bernstein reissued a “market perform” rating and set a $90.00 target price on shares of Edwards Lifesciences in a research report on Monday, November 3rd. Robert W. Baird set a $83.00 price target on Edwards Lifesciences in a research report on Friday, October 31st. Finally, Citigroup lifted their price objective on Edwards Lifesciences from $95.00 to $96.00 and gave the stock a “buy” rating in a research note on Friday, October 31st. Three investment analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $91.39.

Insiders Place Their Bets

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 1,020 shares of the business’s stock in a transaction on Monday, November 10th. The shares were sold at an average price of $82.55, for a total value of $84,201.00. Following the sale, the vice president owned 22,002 shares of the company’s stock, valued at $1,816,265.10. The trade was a 4.43% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CFO Scott B. Ullem sold 13,000 shares of the stock in a transaction on Monday, November 10th. The shares were sold at an average price of $83.08, for a total transaction of $1,080,040.00. Following the completion of the transaction, the chief financial officer owned 39,898 shares of the company’s stock, valued at approximately $3,314,725.84. This represents a 24.58% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 22,970 shares of company stock worth $1,862,878 over the last 90 days. Corporate insiders own 1.29% of the company’s stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.